Mirae Asset Global Investments Co., Ltd. Avidity Biosciences, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $24 Billion
- Q4 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,976 shares of RNA stock, worth $137,887. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,976
Previous 4,236
6.14%
Holding current value
$137,887
Previous $194,000
40.72%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RNA
# of Institutions
249Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$369 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$320 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$299 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$282 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$244 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.81B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...